Literature DB >> 14582845

Mechanistic effect of NMSO3 on replication of human immunodeficiency virus.

Mariko Nakamura1, Masaki Terada, Minori Kamada, Akira Yokono, Shogo Nakamori, Tsuneya Ohno.   

Abstract

NMSO3, a sulphated sialyl lipid, was evaluated for its efficacy against human immunodeficiency virus type 1 (HIV-1). The compound exhibited concentration-dependent inhibition of HIV-1 replication in primary infection cell culture systems. Substantial inhibition was observed at concentrations of NMSO3 that showed little cytotoxicity. NMSO3 also exhibited anti HIV-1 activity in chronically HIV-1 infected cultures. The production of progeny viruses was completely abolished without cytotoxicity by continuous addition of NMSO3 to chronically infected U937 cells. Furthermore, in attempting to define the inhibitory mechanism of NMSO3, we investigated its effect on several steps of the HIV-1 replication cycle. NMSO3 competes with gp120 for binding to CD4 receptors on cells and inhibits the entry of HIV-1. By epitope analysis of the human CD4 molecule, NMSO3 inhibits the binding of antibodies, which recognize the D1 domain of CD4. Moreover, semi-quantitative reverse transcribed polymerase chain reaction (RT-PCR) showed that the integrated provirus is transcriptionally inactive in NMSO3-treated cells, supporting the lack of progeny in the culture supernatant of chronically HIV-1-infected cells treated with NMSO3. These findings indicate that NMSO3 has a unique mechanism of action against HIV-1 in both primary and chronic infection, and may be a valuable compound for the treatment of HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14582845     DOI: 10.1177/095632020301400401

Source DB:  PubMed          Journal:  Antivir Chem Chemother        ISSN: 0956-3202


  2 in total

1.  Development of liposomal nanoconstructs targeting P-selectin (CD62P)-expressing cells by using a sulfated derivative of sialic acid.

Authors:  Saotomo Itoh; Kumi Kawano; Kana Takeshita; Yoshie Maitani; Tsutomu Tsuji
Journal:  Pharm Res       Date:  2014-05-03       Impact factor: 4.200

Review 2.  Targeting RSV with vaccines and small molecule drugs.

Authors:  Heather M Costello; William C Ray; Supranee Chaiwatpongsakorn; Mark E Peeples
Journal:  Infect Disord Drug Targets       Date:  2012-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.